Acute on chronic liver failure and prognostic factors: Time for reevaluation

Revista Espanola de Enfermedades Digestivas

Volumn 103, Issue 4, 2011, Pages 169-176

  Solís Muñoz, Pablo ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; DOBUTAMINE; LEVOSIMENDAN; MILRINONE; NORADRENALIN; TOXIC SUBSTANCE; VASOCONSTRICTOR AGENT;

ACUTE ON CHRONIC LIVER FAILURE; ALCOHOL CONSUMPTION; ANTIBIOTIC THERAPY; APACHE; ARTIFICIAL VENTILATION; ASSISTED VENTILATION; BRAIN EDEMA; CARDIOVASCULAR PARAMETERS; CHRONIC LIVER DISEASE; CONTINUOUS HEMODIAFILTRATION; DISEASE COURSE; DISEASE SEVERITY; DRUG EXPOSURE; EDITORIAL; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL HEMORRHAGE; HEMODYNAMICS; HEPATIC ENCEPHALOPATHY; HEPATORENAL SYNDROME; HUMAN; HYPERALDOSTERONISM; INTENSIVE CARE UNIT; INTRACRANIAL HYPERTENSION; INTUBATION; ISCHEMIA; LIVER DYSFUNCTION; LIVER INJURY; MAYO CLINIC MODEL FOR END STAGE LIVER DISEASE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PATIENT CARE; PATIENT MONITORING; PROGNOSIS; RENAL REPLACEMENT THERAPY; SEDATION; SEPSIS; SEQUENTIAL ORGAN FAILURE ASSESSMENT; SIMPLIFIED ACUTE PHYSIOLOGY SCORE II; SURVIVAL; VIRUS HEPATITIS; FEMALE; GASTROENTEROLOGY; LIVER CIRRHOSIS; MALE; MORTALITY; ORGANIZATION AND MANAGEMENT; SEVERITY OF ILLNESS INDEX;

FEMALE; GASTROENTEROLOGY; HUMANS; INTENSIVE CARE UNITS; LIVER CIRRHOSIS; MALE; SEVERITY OF ILLNESS INDEX;

EID: 80054703129     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (65)

1. Wehler M, Kokoska J, Reulbach U, Hahn EG, Strauss R. Short-term prognosis in critically ill patients with cirrhosis assessed by prognostic scoring systems. Hepatology 2001;34:255-61.
2. O'Grady JG, Schalm SW, Williams R. Acute liver failure: redefining the syndromes. Lancet 1993;342:273-5.
3. Bernal W, Auzinger G, Dhawan A, Wendon J. Acute liver failure. Lancet 2010;376:190-201.
4. Jalan R, Williams R. Acute-on-chronic liver failure: pathophysiological basis of therapeutic options. Blood Purif 2002;20:252-61.
5. Freire P, Romãozinho JM, Amaro P, Ferreira M, Sofia C. Prognostic scores in cirrhotic patients admitted to a gastroenterology intensive care unit. Rev Esp Enferm Dig 2011;103(4):177-83.
6. Freire P, Romãozinho JM, Amaro P, Ferreira M, Sofia C. Prognostic scores in a gastroenterology intensive care unit. Rev Esp Enferm Dig 2010;102:596-601.
7. Duseja A, Chawla YK, Dhiman RK, Kumar A, Choudhary N, Taneja S. Non-hepatic insults are common acute precipitants in patients with acute on chronic liver failure (ACLF). Dig Dis Sci 2010;55:3188-92.
8. Zhu JH, Lei XG. Lipopolysaccharide-induced hepatic oxidative injury is not potentiated by knockout of GPX1 and SOD1 in mice. Biochem Biophys Res Commun 2011;404:559-63.
9. Kamiyama T, Miyakawa H, Tajiri K, Marumo F, Sato C. Ischemic hepatitis in cirrhosis. Clinical features and prognostic implications. J Clin Gastroenterol 1996;22:126-30.
10. Czaja MJ, Xu J, Ju Y, Alt E, Schmiedeberg P. Lipopolysaccharide-neutralizing antibody reduces hepatocyte injury from acute hepatotoxin administration. Hepatology 1994;19:1282-9.
11. Leist M, Gantner F, Naumann H, Bluethmann H, Vogt K, Brigelius-Flohé R, et al. Tumor necrosis factor-induced apoptosis during the poisoning of mice with hepatotoxins. Gastroenterology 1997;112:923-34.
12. Leist M, Gantner F, Bohlinger I, Tiegs G, Germann PG, Wendel A. Tumor necrosis factor induced hepatocite apoptosis precedes liver failure in experimental shock murine models. Am J Pathol 1995;146:1220-34.
13. Tilg H, Jalan R, Kaser A, Davies NA, Offner FA, Hodges SJ, et al. Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol 2003;38:419-25.
14. Mookerjee RP, Tilg H, Williams R, Jalan R. Infliximab and alcoholic hepatitis. Hepatology 2004;40:499-500; author reply 500-1.
15. Vallance P, Moncada S. Hyperdynamic circulation in cirrhosis: a role for nitric oxide? Lancet 1991;337:776-8.
16. Van Berlo CL, Van De Bogaard AE, Van Der Heijden MA, Van Eijk HM, Janssen MA, Bost MC, et al. Is increased ammonia liberation after bleeding in the digestive tract the consequence of complete absence of iso-leucine in hemoglobin? A study in pigs. Hepatology 1989;10:315-23.
17. Olde Damink SW, Jalan R, Deutz NE, Dejong CH, Redhead DN, Hynd P, et al. Isoleucine infusion during "simulated" upper gastrointestinal bleeding improves liver and muscle protein synthesis in cirrhotic patients. Hepatology 2007;45:560-8.
18. Sugarbaker SP, Revhaug A, Wilmore DW. The role of the small intestine in ammonia production after gastric blood administration. Ann Surg 1987;206:5-17.
19. Nance FC, Batson RC, Kline DG. Ammonia production in germ-free Eck fistula dogs. Surgery 1971;70:169-74.
20. Welters CF, Deutz NE, Dejong CH, Soeters PB. Enhanced renal vein ammonia efflux after a protein meal in the pig. J Hepatol 1999;31:489-96.
21. Dejong CH, Meijerink WJ, van Berlo CL, Deutz NE, Soeters PB. Decreased plasma isoleucine concentrations after upper gastrointestinal haemorrhage in humans. Gut 1996;39:13-7.
22. Kohn A. Differential effects of isoleucine deprivation on cell motility, membrane transport and DNA synthesis in NILS8 hamster cells. Exp Cell Res 1975;94:15-22.
23. Gines A, Escorell A, Gines P, Saló J, Jiménez W, Inglada L, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993;105:229-36.
24. Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996;23:164-76.
25. Newby DE, Jalan R, Masumoto S, Hayes PC, Boon NA, Webb DJ. Peripheral vascular tone in patients with cirrhosis: Role of the renin- angiotensin and sympathetic nervous systems. Cardiovasc-Res 1998;38:221-8.
26. Helmy A, Jalan R, Newby DE, Johnston NR, Hayes PC, Webb DJ. Altered peripheral vascular responses to exogenous and endogenous endothelin-1 in patients with well-compensated cirrhosis. Hepatology 2001; 33:826-31.
27. Newby DE, Jalan R, Masumoto S, Hayes PC, Boon NA, Webb DJ. Peripheral vascular tone in patients with cirrhosis: Role of the renin- angiotensin and sympathetic nervous systems. Cardiovasc-Res 1998;38:221-8.
28. Clemersen JO, Larsen FS, Kondrup J, Hansen BA, Ott P. Cerebral herniation in patients with acute liver failure is correlated with arterial amonia concentration. Hepatology 1999;29:648-53.
29. Niederberger M, Ginés P, Martin PY, Tsai P, Morris K, McMurtry I, et al. Comparison of vascular nitric oxide production and systemic hemodynamics in cirrhosis versus prehepatic portal hypertension in rats. Hepato-logy 1996;24:947-51.
30. Laszlo F, Whittle BJ, Evans SM, Moncada S. Association of microvascular leakage with induction of nitric oxide synthase: Effects of nitric oxide synthase inhibitors in various organs. Eur J Pharmacol 1995;283:47-53.
31. Boughton-Smith NK, Evans SM, Laszlo F, Whittle BJ, Moncada S. The induction of nitric oxide synthase and intestinal vascular permeability by endotoxin in the rat. Br J Phamacol 1993;110:1189-95.
32. Mitchell JA, Kohlhaas KL, Sorrentino R, Warner TD, Murad F, Vane JR. Induction by endotoxin of nitric oxide synthase in the rat mesentery: lack of effect on action of vasoconstrictors. Br J Pharmacol 1993;109:265-70.
33. Martin P Y, Ohara M, Gines P, Xu DL, John J, Niederberger M, et al. Nitric oxide synthase (NOS) inhibition for one week improves renal sodium and water excretion in cirrhotic rats with ascites. J Clin Invest 1998;101:235-42.
34. La Villa G, Barletta G, Pantaleo P, Del Bene R, Vizzutti F, Vecchiarino S, et al. Hemodynamic, renal, and endocrine effects of acute inhibition of nitric oxide synthase in compensated cirrhosis. Hepatology 2001;34:19-27.
35. Cunha FQ, Assreuy J, Moss DW, Rees D, Leal LM, Moncada S, et al. Differential induction of nitric oxide synthase in various organs of the mouse during endotoxaemia: role of TNF-a and IL-1-beta. Immunol 1994;81:211-5.
36. Menon KV, Kamath PS. Regional and systemic hemodynamic disturbances in cirrhosis. Clin Liver Dis 2001;5:617-27.
37. MacNaul KL, Hutchinson NI. Differential expression of iNOS and cNOS mRNA in human vascular smooth muscle cells and endothelial cells under normal and inflammatory conditions. Biochem Biophys Res Com-mun 1993;1:1330-4.
38. Annane D, Sanquer S, Sebille V, Faye A, Djuranovic D, Raphaël JC, et al. Compartmentalised inducible nitric-oxide synthase activity in septic shock. Lancet 2000;355:1143-8.
39. O'Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989;97:439-45.
40. Bernal W, Auzinger G, Wendon J. Prognostic utility of the bilirubin lactate and etiology score. Clin Gastro-enterol Hepatol 2009;7:249.
41. Bernuau J, Goudau A, Poynard T, Dubois F, Lesage G, Yvonnet B, et al. Multivariate analysis of prognostic factors in fulminant hepatitis B. Hepatology 1986;6:648-51.
42. Das V, Boelle PY, Galbois A, Guidet B, Maury E, Carbonell N, et al. Cirrhotic patients in the medical intensive care unit: early prognosis and long-term survival. Crit Care Med 2010;38:2108-16.
43. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464-70.
44. Lim YS, Larson TS, Benson JT, Kamath PS, Kremers WK, Therneau TM, et al. Serum sodium, renal function, and survival of patients with end-stage liver disease. J Hepatol 2010;52:523-8.
45. Zipprich A, Kuss O, Rogowski S, Kleber G, Lotterer E, Seufferlein T, et al. Incorporating indocyanin green clearance into the Model for End Stage Liver Disease (MELD-ICG) improves prognostic accuracy in intermediate to advanced cirrhosis. Gut 2010;59:963-8.
46. Biselli M, Gitto S, Gramenzi A, di Dinato R, Brodosi L, Ravaioli M, et al. Six score systems to evaluate candidates with advanced cirrhosis for orthotopic liver transplant: Which is the winner? Liver Transpl 2010;16(8):964-73.
47. Katoonizadeh A, Decaestecker J, Wilmer A, Aerts R, Verslype C, Vansteenbergen W, et al. MELD score to predict outcome in adult patients with non-acetaminophen-induced acute liver failure. Liver Int 2007;27:329-34.
48. Myers RP, Shaheen AA, Aspinall AI, Quinn RR, Burak KW. Gender, renal function, and outcomes on the liver transplant waiting list: Assessment of revised MELD including estimated glomerular filtration rate. J He-patol. 2011 Mar;54(3):462-70.
49. Zheng MH, Shi KQ, Fan YC, Li H, Ye C, Chen QQ, et al. A model to determine 3-month mortality risk in patients with acute-on-chronic hepatitis B liver failure. Clin Gastroenterol Hepatol 2010 Dec 30.
50. Rolando N, Wade J, Davalos M, Wendon J, Philpott-Howard J, Williams R. The systemic inflammatory response syndrome in acute liver failure. Hepatology 2000;32:734-9.
51. Bernal W, Auzinger G, Sizer E, Wendon J. Intensive care management of acute liver failure. Semin Liver Dis 2008;28:188-200.
52. Bernal W, Auzinger G, Dhawan A, Wendon J. Acute liver failure. Lancet 2010;376:190-201.
53. Harry R, Auzinger G, Wendon J. Clinical importance of adrenal insufficiency in acute hepatic dysfunction. Hepatology 2002;36:395-402.
54. Jalan R, Olde Damink SW, Deutz NE, Hayes PC, Lee A. Moderate hypothermia in patients with acute liver failure and uncontrolled intracranial hypertension. Gastroenterology 2004;127:1338-46.
55. Stravitz RT, Larsen FS. Therapeutic hypothermia for acute liver failure. Crit Care Med 2009;37(Supl.):S258-64.
56. Conn HO, Lieberthal MM. The Hepatic Coma Syndromes and Lactulose. Baltimore: Williams & Wilkins; 1979.
57. Tilg H, Jalan R, Kaser A, Davies NA, Offner FA, Hodges SJ, et al. Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol 2003;38:419-25.
58. Lieber CS. Role of oxidative stress and antioxidant therapy in alcoholic and nonalcoholic liver diseases. Adv Pharmacol 1997;38:601-28.
59. Deutz NE, Reijven PL, Bost MC, van Berlo CL, Soeters PB. Modification of the effects of blood on amino acid metabolism by intravenous isoleucine. Gastroenterology 1991;101:1613-20.
60. Bertani H, Gelmini R, Del Buono MG, De Maria N, Girardis M, Solfrini V, et al. Literature overview on artificial liver support in fulminant hepatic failure: a methodological approach. Int J Artif Organs 2002;25:903-10.
61. Schmidt LE, Svendsen LB, Sorensen VR, Hansen BA, Larsen FS. Cerebral blood flow velocity increases during a single treatment with the molecular adsorbents recirculating system in patients with acute on chronic liver failure. Liver Transpl 2001;7:709-12.
62. Mitzner SR, Klammt S, Peszynski P, Hickstein H, Korten G, Stange J, et al. Improvement of multiple organ functions in hepatorenal syndrome during albumin dialysis with the molecular adsorbent recirculating system. Ther Apher 2001;5:417.
63. Schmidt LE, Sorensen VR, Svendsen LB, Hansen BA, Larsen FS. Hemodynamic changes during a single treatment with the molecular adsorbents recirculating system in patients with acute-on-chronic liver failure. Liver Transpl 2001;7:1034-9.
64. Mitzner SR, Stange J, Klammt S, Risler T, Erley CM, Bader BD, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 2000;6:277-86.
65. Fisher RA, Strom SC. Human hepatocyte transplantation: worldwide results. Transplantation 2006;82:441-9.